Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646242 | 0.95 | DPP4 (0.47) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL488953 | 0.74 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL488954 | 0.74 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL1383434 | 0.74 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10326191 | 0.73 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3331450 | 0.73 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL14548972 | 0.73 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL2644964 | 0.73 | TSHR (0.47) | — | |
| SCHEMBL18228451 | 0.73 | HPGD (0.52) | — | |
| SCHEMBL3335449 | 0.73 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | DPP4 91/4885DPP8 64/4885DPP9 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.